Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT05119335 is registered in ClinicalTrials.gov with NiKang Therapeutics, Inc. as lead sponsor.

NCT NCT05119335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05119335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma
Lead sponsor
NiKang Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
October 26, 2021
Completion date
September 30, 2025
Enrollment
120 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, ccrcc, clear cell, clear cell renal cell carcinoma, hif2α inhibitor, hypoxia, hypoxia inducible factor (hif), hypoxia inducible factor 2 alpha (hif-2 alpha), hypoxia inducible factor 2α (hif-2α), kidney cancer, kidney neoplasms, metastatic renal cell carcinoma, recurrent renal cell carcinoma, refractory renal cell carcinoma, renal cancer, renal cell carcinoma, renal neoplasms